Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38224 | 1.00 | SLC7A5 (0.55) | SLC7A5ESR1ESR2ALDH1A1MAPT | |
| SCHEMBL21899391 | 1.00 | SLC7A5 (0.55) | SLC7A5ESR1ESR2ALDH1A1MAPT | |
| SCHEMBL6673760 | 0.87 | ESR1 (0.46) | SLC7A5ESR1ESR2ALDH1A1MAPT | |
| SCHEMBL29800397 | 0.87 | SLC7A5 (0.58) | SLC7A5ESR1ESR2OPRM1OPRK1 | |
| SCHEMBL9834190 | 0.86 | SLC7A5 (0.49) | SLC7A5ESR1ESR2OPRM1OPRK1 | |
| SCHEMBL27669804 | 0.86 | SLC7A5 (0.51) | SLC7A5ESR1ESR2OPRM1OPRK1 | |
| SCHEMBL1081374 | 0.86 | SLC7A5 (0.51) | SLC7A5ESR1ESR2OPRM1OPRK1 | |
| SCHEMBL1081375 | 0.86 | SLC7A5 (0.51) | SLC7A5ESR1ESR2OPRM1OPRK1 | |
| SCHEMBL10197474 | 0.85 | ALDH1A1 (0.46) | ESR1ALDH1A1MAPT | |
| SCHEMBL16743936 | 0.85 | ESR1 (0.56) | SLC7A5ESR1ESR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024177909-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT IN SUBJECTS HAVING A FIBROTIC DISEASE USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20240036055-A1 | Multiplexed DiLeu-Biotin-Azide (DBA) Tag Enabled Isobaric Tandem Orthogonal Proteolysis Activity-Based Protein Profiling (isoBOP-ABPP) Platform For High-Throughput Quantitative Pan-PTM Analysis | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-02-01 | — | — | US | claimed |
| CN-111689929-A | Sulfur fluoride (VI) compound and preparation method thereof | 斯克里普斯研究所 | 2020-09-22 | — | — | CN | claimed |
| EP-1722807-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | Cornell Research Foundation Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20060205669-A1 | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-14 | — | — | US | claimed |
| EP-1419178-B1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIV BERN (CH) | 2006-05-31 | — | — | EP | claimed |
| WO-2006034056-A2 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | UNIVERSITY OF BERN (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1419178-A1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | University of Bern (CH) | 2004-05-19 | — | — | EP | claimed |
| WO-2003014158-A1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIVERSITY OF BERN (CH) | 2003-02-20 | — | — | WO | claimed |
| EP-1283216-A1 | Somatostatin analogues binding to all somatostatin receptor subtypes and their use | Mallinckrodt Inc. (US) | 2003-02-12 | — | — | EP | claimed |
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | SLC7A5 161/4885ESR1 3836/4885ESR2 3097/4885 |
| US-20060205669-A1 | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies | APOB, CCL2, GLP1R | SLC7A5 4471/4885ESR1 2465/4885ESR2 1315/4885 |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | SSTR5, NPY5R, GLP1R | SLC7A5 45/4885ESR1 2918/4885ESR2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.